PAN-Fortis Retrospecitve data collection study for Vaccinated PAN-FORTIS Healthcare Workers infected with SARS-CoV-2 / COVID-19 post vaccinatio
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/10/037377
- Lead Sponsor
- Fortis Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All Vaccinated PAN FORTIS healthcare workers infected with COVID 19
Exclusion Criteria
All non vaccinated PAN FORTIS healthcare workers
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate real world clinical efficacy of COVID vaccines in healthcare workers across Fortis network of hospitals. The assumption being that the health care workers being frontline warriors, are working directly/closely with the patients and have an overall higher risk of exposure to SARS-CoV-2 than the normal individualTimepoint: From Date of 1st or 2nd dose of vaccination to the date of 1st COVID-19 infection
- Secondary Outcome Measures
Name Time Method To actively collate clinical data from Fortis network of hospitals where the healthcare workers got vaccinated but later become infected with COVID 19 infection <br/ ><br>Evaluate severity of disease in Vaccinated Healthcare workers <br/ ><br>c)Efficacy of vaccine post 1 dose administration & after 2nd dose of administrationTimepoint: Duration of COVID-19 infection;To actively collate clinical data from Fortis network of hospitals where the healthcare workers got vaccinated but later become infected with SARS - COVID-19 infection. Clinical data may comprise of structured lab reports, medical images and reports, Clinical Management and Clinical Outcome information. <br/ ><br>Evaluate severity of disease in Vaccinated Healthcare workers <br/ ><br>Efficacy of vaccine post 1 dose administration & after 2nd dose of administration <br/ ><br>Timepoint: Duration of COVID-19 infection